paclitaxel poliglumex

{
  "id": "MLC-T-ONC-006245",
  "term": "paclitaxel poliglumex",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called CT-2103, paclitaxel polyglutamate, and Xyotax.",
    "The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis."
  ],
  "abbreviation": "PG-TXL",
  "synonyms": [
    "CT-2103",
    "paclitaxel polyglutamate",
    "Xyotax",
    "polyglutamate paclitaxel",
    "paclitaxel-polyglutamate polymer",
    "polyglutamic acid paclitaxel",
    "Poly-L-Glutamic acid-Paclitaxel Conjugate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/paclitaxel-poliglumex/"
}